Villani F, Comazzi R, Di Fronzo G, Bertuzzi A, Guindani A
Tumori. 1982 Aug;68(4):349-53. doi: 10.1177/030089168206800414.
Twenty-one patients with various advanced neoplasms were treated with 60 to 75 mg/m2 of doxorubicin every 3 to 4 weeks and monitored by ECG and systolic time intervals (PEP/LVET) with the aim to establish whether a pretreatment with beta-methyldigoxin, administered intermittently, could prevent doxorubicin-induced cardiotoxicity. It was found that until patients received digitalis pretreatment the PEP/LVET ratio did not change significantly from mean basal values even after the highest cumulative dosages of doxorubicin. However, after interruption of the therapy with both drugs, PEP/LVET increased reaching a value not significantly different from that observed in a comparable group of patients treated only with doxorubicin. Moreover, of 9 patients who reached the cumulative limiting dose, 2 developed congestive heart failure. These results question the possibility that digitalis administered according to an intermittent treatment scheme may prevent doxorubicin cardiomyopathy.
21例患有各种晚期肿瘤的患者每3至4周接受60至75mg/m²的阿霉素治疗，并通过心电图和收缩期时间间期（PEP/LVET）进行监测，目的是确定间歇性给予β-甲基地高辛进行预处理是否可以预防阿霉素诱导的心脏毒性。结果发现，在患者接受洋地黄预处理之前，即使在阿霉素累积剂量最高之后，PEP/LVET比值与平均基础值相比也没有显著变化。然而，在用两种药物中断治疗后，PEP/LVET升高，达到的值与仅接受阿霉素治疗的可比患者组中观察到的值没有显著差异。此外，在达到累积限量剂量的9例患者中，有2例发生了充血性心力衰竭。这些结果对按照间歇性治疗方案给予洋地黄可能预防阿霉素心肌病的可能性提出了质疑。
